A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease

PLoS Pathogens

Volumn 5, Issue 12, 2009, Pages

  Kotturi, Maya F ^a   Botten, Jason ^b   Sidney, John ^a   Bui, Huynh Hoa ^a   Giancola, Lori ^a   Maybeno, Matt ^a   Babin, Josie ^a   Oseroff, Carla ^a   Pasquetto, Valerie ^a   Greenbaum, Jason A ^a   Peters, Bjoern ^a   Ting, Joey ^c   Do, Danh ^b   Vang, Lo ^d,e   Alexander, Jeff ^d,e   Grey, Howard ^a   Buchmeier, Michael J ^c   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Epimmune   (United States)

^e PaxVax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; RECOMBINANT VACCINE; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ARENAVIRUS; ARTICLE; CD8+ T LYMPHOCYTE; CROSS REACTION; IMMUNIZATION; MOUSE; NONHUMAN; VACCINATION; VACCINIA VIRUS; ANIMAL; ARENAVIRUS INFECTION; HUMAN; IMMUNOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME; VIRUS HEMORRHAGIC FEVER;

ARENAVIRIDAE; ARENAVIRUS; MUS; MUS MUSCULUS; VACCINIA VIRUS; WHITEWATER ARROYO VIRUS;

ANIMALS; ANTIGENS, VIRAL; ARENAVIRIDAE; ARENAVIRIDAE INFECTIONS; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; EPITOPES; HEMORRHAGIC FEVERS, VIRAL; HLA-A ANTIGENS; HUMANS; IMMUNIZATION; MICE; MICE, TRANSGENIC; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 74549148011     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000695     Document Type: Article

References (51)

1. Charrel RN, de Lamballerie X, Emonet S (2008) Phylogeny of the genus Arenavirus. Curr Opin Microbiol 11: 362-368.
2. Southern PJ (1996) Fields Virology; Fields BN, Knipe DM, Howley PM, eds. Philadelphia: Lippencott-Raven. pp 1505-1519.
3. Barton LL, Hyndman NJ (2000) Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen. Pediatrics 105: E35.
4. Barton LL, Mets MB, Beauchamp CL (2002) Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am J Obstet Gynecol 187: 1715-1716.
5. Bonthius DJ, Wright R, Tseng B, Barton L, Marco E, et al. (2007) Congenital lymphocytic choriomeningitis virus infection: spectrum of disease. Ann Neurol 62: 347-355.
6. Gonzalez JP, Emonet S, de Lamballerie X, Charrel R (2007) Arenaviruses. Curr Top Microbiol Immunol 315: 253-288.
7. Walsh CM, Matloubian M, Liu CC, Ueda R, Kurahara CG, et al. (1994) Immune function in mice lacking the perforin gene. Proc Natl Acad Sci U S A 91: 10854-10858.
8. Kotturi MF, Peters B, Buendia-Laysa F, Jr., Sidney J, Oseroff C, et al. (2007) The CD8+ T-cell response to lymphocytic choriomeningitis virus involves the L antigen: uncovering new tricks for an old virus. J Virol 81: 4928-4940.
9. Botten J, Alexander J, Pasquetto V, Sidney J, Barrowman P, et al. (2006) Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol 80: 8351-8361.
10. Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, et al. (2007) HLAA2-Restricted Protection against Lethal Lymphocytic Choriomeningitis. J Virol 81: 2307-2317.
11. Clegg JC (1992) Current progress towards vaccines for arenavirus-caused diseases. Vaccine 10: 89-95.
12. Fisher-Hoch SP, McCormick JB (2001) Towards a human Lassa fever vaccine. Rev Med Virol 11: 331-341.
13. Maiztegui JI, McKee KT, Jr., Barrera Oro JG, Harrison LH, Gibbs PH, et al. (1998) Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 177: 277-283.
14. McKee KT, Jr., Oro JG, Kuehne AI, Spisso JA, Mahlandt BG (1993) Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques. Am J Trop Med Hyg 48: 403-411.
15. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, et al. (2005) Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 57: 304-314.
16. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 201-212.
17. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW (1991) Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 173: 1007-1015.
18. Alexander J, Oseroff C, Sidney J, Wentworth P, Keogh E, et al. (1997) Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. J Immunol 159: 4753-4761.
19. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, et al. (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153: 5586-5592.
20. Braud VM, McMichael AJ, Cerundolo V (1998) Differential processing of influenza nucleoprotein in human and mouse cells. Eur J Immunol 28: 625-635.
21. Sidney J, Peters B, Frahm N, Brander C, Sette A (2008) HLA class I supertypes: a revised and updated classification. BMC Immunol 9: 1.
22. Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, et al. (2006) Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics 7: 153.
23. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320: 760-764.
24. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567.
25. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, et al. (1984) Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653-669.
26. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, et al. (2000) Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol 152: 793-799; discussion 804.
27. Roose K, Fiers W, Saelens X (2009) Pandemic preparedness: Toward a universal influenza vaccine. Drug News Perspect 22: 80-92.
28. Charatan F (2009) UN warns that swine flu outbreak could turn into pandemic. BMJ 338: b1751.
29. Van Reeth K, Van Gucht S, Pensaert M (2002) Correlations between lung proinflammatory cytokine levels, virus replication, and disease after swine influenza virus challenge of vaccination-immune pigs. Viral Immunol 15: 583-594.
30. Ourmanov I, Kuwata T, Goeken R, Goldstein S, Iyengar R, et al. (2009) Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody. J Virol 83: 5388-5400.
31. Botten JW, Kotturi MF (2007) Adaptive immunity to Lymphocyctic choriomeningitis virus: new insights into antigenic determinants. Future Virology 2: 495-508.
32. Man S, Newberg MH, Crotzer VL, Luckey CJ, Williams NS, et al. (1995) Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int Immunol 7: 597-605.
33. Kotturi MF, Assarsson E, Peters B, Grey H, Oseroff C, et al. (2009) Of mice and humans: how good are HLA transgenic mice as a model of human immune responses? Immunome Res 5: 3.
34. Pasquetto V, Bui HH, Giannino R, Banh C, Mirza F, et al. (2005) HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol 175: 5504-5515.
35. Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, et al. (2006) A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol 24: 817-819.
36. Bui HH, Botten J, Fusseder N, Pasquetto V, Mothe B, et al. (2007) Protein sequence database for pathogenic arenaviruses. Immunome Res 3: 1.
37. Delgado S, Erickson BR, Agudo R, Blair PJ, Vallejo E, et al. (2008) Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog 4: e1000047. doi:10.1371/journal.ppat. 1000047.
38. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, et al. (2009) Genetic detection and characterization of Lujo virus, a new hemorrhagic feverassociated arenavirus from southern Africa. PLoS Pathog 5: e1000455. doi:10.1371/journal.ppat.1000455.
39. Jahrling PB, Peters CJ (1986) Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development. Med Microbiol Immunol 175: 165-167.
40. Selin LK, Varga SM, Wong IC, Welsh RM (1998) Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 188: 1705-1715.
41. ter Meulen J, Badusche M, Kuhnt K, Doetze A, Satoguina J, et al. (2000) Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol 74: 2186-2192.
42. Yu XG, Lichterfeld M, Perkins B, Kalife E, Mui S, et al. (2005) High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level. AIDS 19: 1449-1456.
43. Coplan PM, Gupta SB, Dubey SA, Pitisuttithum P, Nikas A, et al. (2005) Crossreactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 191: 1427-1434.
44. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, et al. (2005) Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79: 2956-2963.
45. Siddiqui MA, Perry CM (2006) Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 66: 1263-1271; discussion 1272-1263.
46. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, et al. (1996) Definition of an HLA-A3-like supermotif demonstrates the overlapping peptidebinding repertoires of common HLA molecules. Hum Immunol 45: 79-93.
47. Sidney J, Southwood S, Oseroff C, Guercio MFD, Sette A, et al. (1998) Measurement of MHC/peptide interactions by gel filtration. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology I. New York: John Wiley & Sons. pp 18.13.11-18.13.19.
48. Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, et al. (2001) Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 62: 1200-1216.
49. Whitton JL, Southern PJ, Oldstone MB (1988) Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus. Virology 162: 321-327.
50. Blasco R, Moss B (1995) Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158: 157-162.
51. Tangri S, Ishioka GY, Huang X, Sidney J, Southwood S, et al. (2001) Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 194: 833-846.